Shots:

• Health Canada has approved Dupixent for the treatment of mod. to sev. AD in children aged 6 to 11yrs. whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
• The approval marks the fifth indication for Dupixent in Canada following the approvals for AD in adults and adolescents- severe chronic rhinosinusitis with nasal polyposis- and severe asthma in adults and adolescents
• The results from a survey in Canadian children showed 70% experienced the loss of sleep and 30% experienced anxiety. Dupixent is a mAb targeting IL-4 and IL-13 proteins and is not an immunosuppressant

 ­ Ref: Newswire Canada | Image: Global Competition Review